Introduction {#s1}
============

Osteoarthritis (OA) is a major source of pain, disability and socioeconomic costs worldwide[@R1] and commonly affects footballers, rugby players and other athletes.[@R2] Oral non-steroidal anti-inflammatory drugs (NSAIDs) are recommended for OA pain,[@R5] but their safety concerns often outweigh their benefits.[@R11] Concerns over the gastrointestinal (GI) risk of oral traditional NSAIDs are widely accepted,[@R12] and selective cyclooxygenase-2 (COX-2) inhibitors were developed as an alternative to reduce this risk. COX-2 inhibitors, however, are associated with an increased risk of cardiovascular (CV) events.[@R13] It is therefore suggested that both oral NSAIDs and COX-2 inhibitors should be prescribed with a proton pump inhibitor in patients with a high risk of GI bleeding.[@R18] However, the issues associated with polypharmacy and the additional costs of this combination therapy limit their use.[@R21]

Topical NSAIDs offer an alternative to decrease the risk of systemic NSAIDs.[@R22] Although topical NSAIDs are considered relatively safe, their skin adverse effects (AEs) cannot be ignored (ranging from 10% to 39%).[@R23] With respect to systemic AEs, GI bleeding, dyspepsia, acute renal impairment and asthma have been reported in relation to topical NSAIDs.[@R25] Furthermore, the prevalence of systemic AEs in the older population has been reported to be as high as 17.5%, of which 2%--9% may be GI AEs.[@R24] However, these studies did not have control groups and the risk cannot be wholly attributed to the use of topical NSAIDs. Therefore, the safety profile of topical NSAIDs remains unclear.

The Osteoarthritis Research Society International guidelines consider topical NSAIDs to be safer and better tolerated than oral NSAIDs in knee OA.[@R6] In UK, the National Institute for Health and Care Excellence (NICE) recommend topical NSAIDs ahead of systemic analgesics (ie, paracetamol, oral NSAIDs, COX-2 inhibitors and opioids) for knee and hand OA.[@R5] In 2004, we conducted a conventional meta-analysis and found that topical NSAIDs were effective for OA pain, but the efficacy only remained significant in the first 2 weeks of application when compared with placebo.[@R28] Due to the limited number of trials (13) included at the time, the results may not be conclusive. More recently, a meta-analysis of 215 trials reported that topical NSAIDs exhibited the largest overall treatment effect (ie, specific treatment effect plus contextual effect) for pain relief in OA among 11 representative treatments, including complementary, pharmacological, non-pharmacological and surgical treatments.[@R29] Although recommended and known to be effective, it is still a challenge to choose a particular topical NSAID when faced with so many available options that vary in terms of the contained NSAID, carrier and mode of application (eg, cream, gel and patch).

A recent Cochrane systematic review examined the efficacy and safety of topical NSAIDs in chronic musculoskeletal pain.[@R30] However, it was not specific to OA and could not compare the relative efficacy between topical NSAIDs as it was not a network meta-analysis. Furthermore, it used only randomised controlled trials (RCTs) for safety assessment. RCTs are only relevant for AEs with a high incidence, while observational studies are required for AEs that occur with moderate-low incidence and that require longer term to occur.

We undertook this systematic review and network meta-analysis of RCTs and observational studies and have ranked the topical NSAIDs (including salicylate) based on the results.

Methods {#s2}
=======

Literature search {#s2a}
-----------------

Systematic literature searches were undertaken using PubMed, Embase, Cochrane Library and Web of Science. Search strategies, using a series of keywords related to topical NSAIDs (including salicylate), formulations and study designs, were used to identify relevant RCTs in patients with OA and relevant observational studies in any condition (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}) from 1966 to January 2017. The database search was supplemented by subsequent periodic scrutiny of unpublished and ongoing RCTs from the WHO International Clinical Trials Registry (ICTRP) (<http://apps.who.int/trialsearch/>). In addition, references of the retrieved papers and reviews were manually reviewed.
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Inclusion/exclusion criteria {#s2b}
----------------------------

The inclusion criteria for RCTs were as follows: (1) RCTs; (2) studies on patients with OA at any joint; (3) studies comparing topical NSAIDs (including salicylate) with placebo or each other; (4) studies reporting pain, function or AE outcomes in patients and (5) studies published in any language. The following studies were excluded: (1) secondary analyses, including some combined data analyses of published RCTs; (2) studies where the follow-up time was less than 1 week; (3) cross-over design studies; (4) topical NSAIDs combined with other drugs; (5) studies for postoperative pain and (6) abstract only (insufficient data).

The inclusion criteria for observational studies were as follows: (1) observational studies (case-control, nested case-control, cross-sectional, cohort or longitudinal studies); (2) studies comparing topical NSAIDs (including salicylate) with no treatment or each other; (3) studies reporting any AE outcomes in humans and (4) studies published in any language. The following studies were excluded: (1) ophthalmological conditions and (2) abstract only.

Quality assessment {#s2c}
------------------

The Cochrane risk of the bias assessment tool was used to determine the methodological quality of RCTs.[@R31] A total of six domains were evaluated: random sequence generation, allocation concealment, participant blinding, outcome assessor blinding, incomplete outcome data and selective reporting. Each domain was assigned a judgement of low risk of bias, high risk of bias or unclear risk of bias. The judgments for each domain were made strictly following the Cochrane Handbook V.5.1.0, Chapter 8.5.[@R31]

The methodological quality of the observational studies was evaluated using the Newcastle-Ottawa Scale (NOS),[@R32] which was developed to assess the quality of non-randomised studies based on three broad domains: selection of the study groups, comparability among different groups and ascertainment of either the exposure or outcome of interest. The total score of NOS ranges from 0 to 9 based on its assessment items.

Outcome measures {#s2d}
----------------

For RCTs, the primary outcome was pain relief. The secondary outcome was functional improvement. The change-from-baseline score at the last follow-up period was used/calculated. If a study reported multiple pain scales, the scale with the highest sensitivity to change was used.[@R33] The function subscale of Western Ontario and McMaster Universities Arthritis Index (WOMAC) was used for the assessment of functional improvement. If a study did not measure or report WOMAC function, the Lequesne Index or one of the other functional measurement scales was used instead. If the original paper was unavailable/unpublished, the outcomes were extracted from systematic reviews and meta-analyses, if available.[@R30] If a study involved multiple treatment groups with different doses of the same drug, the data were combined into one treatment group. Only differences between two treatment arms were calculated. As different scales were used for the same outcome, the standardised mean difference (SMD) was calculated.[@R31]

To determine the safety and tolerability of topical NSAIDs, data from both RCTs and observational studies were analysed separately. The number of participants who experienced any AE (including local, GI, CV and renal AEs) and withdrawals due to AEs were calculated per group. The adjusted OR for any AE was derived for the safety of topical NSAIDs versus placebo/control. If unavailable, the crude OR was selected instead.

Statistical analysis {#s2e}
--------------------

A conventional meta-analysis was conducted to compare topical NSAIDs overall with placebo (in RCTs) and with no treatment (in observational studies). The heterogeneity of the effect size across the studies was tested using the Q statistic (P\<0.05 was considered heterogeneous) and I^2^ statistic (I^2^ \>50% was considered heterogeneous). If there was significant heterogeneity between studies, a random-effects model was used; otherwise, a fixed-effects model was used. Subgroup analyses of topical NSAIDs versus placebo at different follow-up periods (week 1 to week 4 and over 4 weeks) were conducted.

The Bayesian network meta-analysis methods have been described in our previous research.[@R15] The methods used can increase the number of studies within each comparison, thereby narrowing the width of the CI of the estimate.[@R36] The Markov Chain Monte Carlo method was used to estimate posterior densities for unknown variables.[@R39] A random effects model was adopted as the most appropriate and conservative analysis method to assess differences between trials. Two Markov chains ran simultaneously with different initial values, which were chosen arbitrarily for convergence. A total of 50 000 simulations were generated for each of the two sets of initial values, and the first 10 000 simulations were discarded due to the burn-in period. The WinBUGS codes are available at <http://www.bristol.ac.uk/social-community-medicine/projects/mpes/> (online [supplementary appendix 2](#SP1){ref-type="supplementary-material"}). The overall effect sizes (SMDs or ORs) were generated from the median of the posterior distribution. The 2.5th and 97.5th percentiles of the posterior distribution were considered the lower and upper limit, respectively, of the traditional corresponding 95% CI. Significant differences were identified when the 95% CI did not include 0 for SMD or 1 for OR. Heterogeneity was defined as the variability of results across trials, with τ^2^\<0.04 indicating a low level and τ^2^\>0.4 a high level.[@R43] When trials contained three or more treatment arms, inconsistency was defined by the differences between direct and indirect effect estimates for the same comparison.[@R44] The fit of the model to the data was measured by calculating the posterior mean residual deviance.[@R45] Rankings for all evaluated treatments were based on the level of effect according to their posterior probabilities. Surface under the cumulative ranking (SUCRA) is equal to 100% for the best treatment and 0% for the worst treatment.[@R44] Subgroup analyses were conducted by restricting studies to only those who enrolled knee OA or hand OA participants, to non-commercially funded studies and to studies with efficacy data at 1 or 2 weeks. Network meta-regressions were conducted to consider the potential impact of pain and function level at baseline, length of follow-up time and treatment duration.[@R47]

All statistical analyses were conducted using WinBUGS software (V.1.4.3, MRC Biostatistics Unit, Cambridge, UK), STATA software (V.11.0, Stata, College Station, Texas, USA) and Review Manager 5.3 software (RevMan 5.3, The Cochrane Collaboration, Oxford, UK).

Results {#s3}
=======

Study selection and characteristics of the included studies {#s3a}
-----------------------------------------------------------

Forty-three studies, comprising 36 RCTs (7900 patients with OA) and 7 observational studies (218 074 participants), were included. [Figure 1](#F1){ref-type="fig"} depicts the details of the selection process. Twelve topical therapies (ibuprofen, diclofenac patch, diclofenac gel, diclofenac solution, ketoprofen, eltenac, nimesulide, indomethacin, etoricoxib, piroxicam, salicylate and placebo) were evaluated for OA in the included RCTs ([figure 2](#F2){ref-type="fig"}). The characteristics of the included comparisons are shown in [table 1](#T1){ref-type="table"} and detailed information on the included RCTs and observational studies is shown in online [supplementary appendix 3](#SP1){ref-type="supplementary-material"}. The methodological quality was evaluated for all included trials and observational studies (online [supplementary appendix 4](#SP1){ref-type="supplementary-material"}).

![Study selection process. ICTRP, International Clinical Trials Registry; OA, osteoarthritis; RCT, randomised controlled trials.](bjsports-2017-098043f01){#F1}

![Structure of network formed by interventions. The lines between treatment nodes indicate the direct comparisons made within randomised controlled trials. Numbers (n/n) near the line indicate 'number of trials/number of participants' of the related comparisons.](bjsports-2017-098043f02){#F2}

###### 

Characteristics of the included comparisons in RCTs and the results of conventional meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Comparison                       No. of trials   No. of pts   Target joint        Mean age (range)   Female %   Mean FU periods\   SMD (95% CI) for pain   SMD (95% CI) for function
                                                                                                                  (weeks, range)                             
  -------------------------------- --------------- ------------ ------------------- ------------------ ---------- ------------------ ----------------------- ---------------------------
  Diclofenac patch vs placebo      2               258          Knee                65.2 (64--67)      69.8       2                  −0.94\                  −0.55\
                                                                                                                                     (−1.20 to --0.68)       (−0.81 to --0.30)

  Ibuprofen vs placebo             3               225          Knee                63.9 (60.8--67)    63.5       1.3 (1--2)         −0.66\                  −0.72\
                                                                                                                                     (−1.06 to --0.25)       (−1.00 to --0.44)

  Piroxicam vs placebo             3               421          Knee or lumbar      51                 64.5       2                  −0.50\                  −1.07\
                                                                                                                                     (−0.82 to --0.19)       (−1.40 to --0.74)

  Nimesulide vs placebo            1               70           Knee                53.6               84.3       4                  −0.39\                  −0.49\
                                                                                                                                     (−0.90 to 0.13)         (−1.01 to 0.03)

  Diclofenac gel vs placebo        7               1783         Multiple joints     61.3 (52--67)      69.2       6 (2--12)          −0.30\                  −0.36\
                                                                                                                                     (−0.39 to --0.20)       (−0.46 to --0.27)

  Diclofenac solution vs placebo   6               1402         Knee                62.8 (60.2--65)    63.8       7.3 (4--12)        −0.29\                  −0.32\
                                                                                                                                     (−0.40 to --0.18)       (−0.43 to --0.21)

  Ketoprofen vs placebo            6               2787         Knee                61.5 (59--63.3)    67.9       8 (2--12)          −0.10\                  −0.04\
                                                                                                                                     (−0.30 to 0.11)         (−0.12 to 0.05)

  Salicylate vs placebo            1               116          Knee or hip         65.7               55.2       4                  −0.08\                  NR
                                                                                                                                     (−0.45 to 0.29)         

  Eltenac vs placebo               2               437          Knee                64.5 (61--67)      72.3       4                  −0.02\                  −0.37\
                                                                                                                                     (−0.23 to 0.18)         (−0.58 to --0.17)

  Etoricoxib vs placebo            1               48           Knee                61.4               68.8       4                  0.04\                   0.13\
                                                                                                                                     (−0.53 to 0.60)         (−0.44 to 0.69)

  Indomethacin vs diclofenac gel   1               99           Knee, hip or hand   54.2               68.7       2                  0.29\                   0.38\
                                                                                                                                     (−0.11 to 0.69)         (−0.03 to 0.78)

  Indomethacin vs placebo          1               100          Knee or ankle       NR                 72         2                  NR                      NR

  Ketoprofen vs diclofenac gel     1               85           Knee                57.1               84.7       4                  NR                      −0.13\
                                                                                                                                                             (−1.48 to --0.58)

  Piroxicam vs diclofenac gel      1               69           Knee                56.5               60.9       4                  NR                      NR
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FU, follow-up; No. of pts, number of participants included; No. of trials, number of trials included; NR, not reported; RCTs, randomised controlled trials; SMD, standardised mean difference.

Effects on pain relief in RCTs (vs placebo at last follow-up point) {#s3b}
-------------------------------------------------------------------

A total of 29 trials involving all 12 topical therapies were analysed.

### Conventional meta-analysis {#s3b1}

Topical NSAIDs overall were superior to placebo for pain relief (SMD=−0.30, 95% CI −0.40 to −0.20) (online [supplementary appendix 5](#SP1){ref-type="supplementary-material"}). Subgroup analysis further indicated that statistically significant differences were evident at weeks 1, 2, 3, 4 and over 4 weeks (online [supplementary appendix 5](#SP1){ref-type="supplementary-material"}). Diclofenac patch exhibited the largest effect for pain relief (SMD=−0.94, 95% CI −1.20 to −0.68) ([table 1](#T1){ref-type="table"}).

### Network meta-analysis {#s3b2}

Diclofenac patch was most effective for pain relief (SMD=−0.81, 95% CI −1.12 to −0.52) ([figure 3](#F3){ref-type="fig"}). The detailed results are illustrated in [table 2](#T2){ref-type="table"} and the rankings based on SUCRA are shown in online [supplementary appendix 6](#SP1){ref-type="supplementary-material"}. Diclofenac patch had the largest probability of being the best treatment option (SUCRA=95.7%), followed by ibuprofen cream (SUCRA=88.81%). Network meta-regression showed that there were no significant interactions between pain relief and baseline pain level or length of follow-up time (online [supplementary appendix 7](#SP1){ref-type="supplementary-material"}). There was no evidence of high heterogeneity among the trials (τ^2^=0.01). Evaluation of the goodness of fit demonstrated a good fit with a posterior mean residual deviance of 61.31 (58 data points). Subgroup analysis of studies with patients with knee OA and studies with efficacy data at 1 or 2 weeks did not reveal any substantial change (online [supplementary appendix 8](#SP1){ref-type="supplementary-material"}). Only one trial[@R50] investigated the effects of topical diclofenac gel on patients with hand OA (SMD=−0.20, 95% C: −0.40 to 0.00). After excluding commercially funded/sponsored trials (17 trials), only diclofenac patch was statistically superior to placebo for pain relief (SMD=−0.82, 95% CI −1.65 to −0.03) (online [supplementary appendix 8](#SP1){ref-type="supplementary-material"}).

![(A) Network meta-analysis of pain relief for different active interventions compared with placebo in randomised controlled trials. The number of trials and number of participants (pts) involved in the direct comparisons (vs placebo) were: diclofenac patch (two trials, 245 pts), ibuprofen (three trials, 214 pts), piroxicam (one trial, 179 pts), nimesulide (one trial, 70 pts), diclofenac gel (seven trials, 1776 pts), diclofenac solution (five trials, 1272 pts), ketoprofen (five trials, 2614 pts), salicylate (one trial, 114 pts), eltenac (two trials, 437 pts), indomethacin (none) and etoricoxib (one trial, 48 pts), and the number of trials and number of participants involved in the indirect comparisons were: diclofenac gel versus indomethacin (one trial, 98 pts). (B) Network meta-analysis of treatment effects on functional improvement for different active interventions compared with placebo. The number of trials and number of participants (pts) involved in the direct comparisons (vs placebo) were: piroxicam (one trial, 179 pts), ibuprofen (three trials, 211 pts), diclofenac patch (two trials, 245 pts), nimesulide (one trial, 70 pts), eltenac (two trials, 437 pts), diclofenac solution (five trials, 1272 pts), diclofenac gel (six trials, 1657 pts), ketoprofen (four trials, 2583 pts), etoricoxib (one trial, 48 pts) and indomethacin (none). The number of trials and number of participants involved in the indirect comparisons was: diclofenac gel versus indomethacin (one trial, 98 pts) and diclofenac gel versus ketoprofen (one trial, 85 pts). SMD, standardised mean difference.](bjsports-2017-098043f03){#F3}

###### 

Detailed results of network meta-analysis for pain (white) and function (grey)

  ----------------- --------------------- ------------------- ----------------- ------------------- ------------------- ----------------- ------------------- ------------------- ------------------- ------------------ -------------------
  Diclofenac gel    −0.01\                0.51\               −0.21\            −0.27\              0.38\               0.10\             −0.22\              −0.34\              −0.31\              0.20\              −0.30\
                    (−0.21 to 0.19)       (0.19 to 0.84)      (−0.41 to 0.00)   (−0.57 to 0.01)     (0.05 to 0.71)      (−0.47 to 0.66)   (−0.68 to 0.23)     (−0.97 to 0.28)     (−0.80 to 0.15)     (−0.22 to 0.61)    (−0.44 to --0.17)

  0.12\             Diclofenac solution   0.53\               −0.20\            −0.26\              0.39\               0.11\             −0.21\              −0.33\              −0.30\              0.21\              −0.29\
  (−0.18 to 0.44)                         (0.20 to 0.86)      (−0.39 to 0.03)   (−0.56 to 0.04)     (0.05 to 0.73)      (−0.46 to 0.68)   (−0.66 to 0.25)     (−0.96 to 0.30)     (−0.82 to 0.23)     (−0.21 to 0.63)    (−0.44 to --0.14)

  0.35\             0.23\                 Diclofenac patch    −0.72\            −0.79\              −0.13\              −0.42\            −0.74\              −0.86\              −0.83\              −0.32\             −0.81\
  (−0.11to 0.82)    (−0.24 to 0.7)                            (−1.05 to 0.39)   (−0.19 to --0.40)   (−0.56 to 0.28)     (−1.04 to 0.21)   (−1.26 to --0.22)   (−1.53 to --0.18)   (−1.40 to --0.26)   (−0.81 to 0.17)    (−1.12 to --0.52)

  −0.02\            −0.14\                −0.37\              Ketoprofen        −0.06\              0.59\               0.31\             −0.01\              −0.13\              −0.10\              0.41\              −0.09\
  (−0.29 to 0.31)   (−0.45 to 0.22)       (−0.82 to 0.13)                       (−0.37 to 0.22)     (0.24 to 0.99)      (−0.26 to 0.87)   (−0.48 to 0.44)     (−0.77 to 0.49)     (−0.63 to 0.41)     (−0.02 to 0.82)    (−0.25 to 0.04)

  0.16\             0.05\                 −0.18\              0.19\             Eltenac             0.65\               0.37\             0.05\               −0.07\              −0.04\              0.47\              −0.03\
  (−0.26 to 0.61)   (−0.4 to 0.49)        (−0.74 to 0.38)     (−0.28 to 0.61)                       (0.26 to 1.05)      (−0.23 to 0.98)   (−0.45 to 0.56)     (−0.73 to 0.62)     (−0.60 to 0.52)     (0.00 to 0.94)     (−0.28 to 0.23)

  0.52\             0.4\                  0.17\               0.54\             0.36\               Ibuprofen           −0.28\            −0.60\              −0.72\              −0.69\              −0.18\             −0.68\
  (0.1 to 0.96)     (−0.04 to 0.85)       (−0.38 to 0.73)     (0.08 to 0.97)    (−0.18 to 0.89)                         (−0.91 to 0.35)   (−1.12 to --0.07)   (−1.40 to --0.03)   (−1.28 to 0.11)     (−0.68 to 0.31)    (−0.98 to --0.38)

  0.33\             0.21\                 −0.02\              0.35\             0.17\               −0.19\              Nimesulide        −0.32\              −0.44\              −0.41\              0.10\              −0.40\
  (−0.34 to 1.02)   (−0.48 to 0.9)        (−0.78 to 0.75)     (−0.35 to 1.03)   (−0.59 to 0.92)     (−0.94 to 0.56)                       (−1.02 to 0.38)     (−1.26 to 0.37)     (−1.16 to 0.34)     (−0.58 to 0.78)    (−0.95 to 0.15)

  --                                      --                  --                --                  --                  --                Salicylate          −0.12\              −0.09\              0.42\              −0.08\
                                                                                                                                                              (−0.86 to 0.64)     (−0.75 to 0.56)     (−0.17 to 1.01)    (−0.51 to 0.35)

  −0.35\            −0.46\                −0.69\              −0.32\            −0.51\              −0.87\              −0.68\            --                  Etoricoxib          0.03\               0.54\              0.04\
  (−1.09 to 0.41)   (−1.22 to 0.29)       (−1.52 to 0.13)     (−1.1 to 0.42)    (−1.33 to 0.31)     (−1.69 to --0.05)   (−1.65 to 0.29)                                           (−0.76 to 0.81)     (−0.19 to 1.26)    (−0.57 to 0.65)

  −0.39\            −0.51\                −0.73\              −0.36\            −0.55\              −0.91\              −0.72\            --                  −0.04\              Indomethacin        0.51\              0.01\
  (−0.98 to 0.2)    (−1.19 to 0.15)       (−1.49 to 0.00)     (−1.06 to 0.26)   (−1.3 to 0.17)      (−1.65 to --0.19)   (−1.63 to 0.18)                       (−1.0 to 0.91)                          (−0.12 to 1.15)    (−0.48 to 0.51)

  0.83\             0.71\                 0.48\               0.85\             0.66\               0.3\                0.49\             --                  1.17\               1.21\               Piroxicam          −0.50\
  (0.24 to 1.44)    (0.1 to 1.31)         (−0.21 to 1.17)     (0.22 to 1.43)    (−0.01 to 1.34)     (−0.37 to 0.99)     (−0.37 to 1.35)                       (0.25 to 2.09)      (0.38 to 2.07)                         (−0.89 to --0.11)

  −0.22\            −0.33\                −0.56\              −0.19\            −0.38\              −0.74\              −0.55\            --                  0.13\               0.17\               −1.04\             Placebo
  (−0.42 to 0.00)   (−0.57 to --0.1)      (−0.97 to --0.15)   (−0.45 to 0.02)   (−0.76 to 0.00)     (−1.12 to --0.36)   (−1.2 to 0.1)                         (−0.59 to 0.85)     (−0.44 to 0.81)     (−1.6 to --0.48)   
  ----------------- --------------------- ------------------- ----------------- ------------------- ------------------- ----------------- ------------------- ------------------- ------------------- ------------------ -------------------

Data are standardised mean difference (from the top left to the bottom right, higher comparator vs lower comparator) and their related 95% CI.

Effects on functional improvement in RCTs (vs placebo at last follow-up point) {#s3c}
------------------------------------------------------------------------------

A total of 27 trials involving 11 topical therapies (all except salicylate) were analysed.

### Conventional meta-analysis {#s3c1}

Topical NSAIDs overall had a significantly better effect than placebo (SMD=−0.35, 95% CI −0.45 to −0.24) (online [supplementary appendix 5](#SP1){ref-type="supplementary-material"}). Subgroup analysis further indicated that significant differences were evident at weeks 1, 2, 3, 4 and over 4 weeks (online [supplementary appendix 5](#SP1){ref-type="supplementary-material"}). Piroxicam (SMD=−1.07, 95% CI −1.40 to −0.74) exhibited the largest effect for functional improvement ([table 1](#T1){ref-type="table"}).

### Network meta-analysis {#s3c2}

Piroxicam was the best treatment for functional improvement (SMD=−1.04, 95% CI −1.60 to −0.48) ([figure 3](#F3){ref-type="fig"}). The detailed results are illustrated in [table 2](#T2){ref-type="table"}. The ranking based on SUCRA is shown in online [supplementary appendix 6](#SP1){ref-type="supplementary-material"}. Piroxicam had the largest probability of being the best treatment option (SUCRA=95.6%), followed by ibuprofen cream (SUCRA=84.4%) and diclofenac patch (SUCRA=72.6%). Network meta-regression showed no significant interactions between functional improvement and baseline function level or length of follow-up (online [supplementary appendix 7](#SP1){ref-type="supplementary-material"}). There was no evidence of high heterogeneity among trials (τ^2^=0.05). Evaluation of the goodness of fit demonstrated a good fit with a posterior mean residual deviance of 58.12 (54 data points). Subgroup analysis of knee OA studies and studies with efficacy data at 1 or 2 weeks did not reveal any substantial change (online [supplementary appendix 8](#SP1){ref-type="supplementary-material"}). Only one trial[@R50] on diclofenac gel was restricted to patients with hand OA (SMD=−0.26, 95% CI −0.46 to −0.06). After excluding the trials funded/sponsored by commercial companies (16 trials), no active treatment was superior to placebo for functional improvement (online [supplementary appendix 8](#SP1){ref-type="supplementary-material"}).

Adverse effects in RCTs (vs placebo at last follow-up point) {#s3d}
------------------------------------------------------------

A total of 31 trials involving 11 topical therapies (all except etoricoxib) reported AEs.

### Conventional meta-analysis {#s3d1}

Topical NSAID s overall did not show a significantly higher risk for skin (OR=1.38, 95% CI 0.99 to 1.92), GI or CV AEs (online [supplementary appendix 5](#SP1){ref-type="supplementary-material"}). However, the withdrawal rate due to AE was significantly higher (OR=1.56, 95% CI 1.21 to 2.00).

### Network meta-analysis {#s3d2}

Apart from salicylate gel (OR=16.83, 95% CI 2.12 to 499.3) which had greater withdrawal due to AE rates compared with placebo, topical NSAIDs had neither more withdrawals due to AE nor higher incidence of AEs (such as skin, GI and CV events) ([table 3](#T3){ref-type="table"}). The relative safety between different topical NSAIDs can be seen in online [supplementary appendix 8](#SP1){ref-type="supplementary-material"}. The network meta-regression showed that there was no significant interaction between treatment duration and AEs (online [supplementary appendix 7](#SP1){ref-type="supplementary-material"}). Only one RCT[@R51] reported the risk of renal AEs and the results showed no significant risk of renal or urinary disorders associated with the use of topical ketoprofen (100, 50 or 25 mg).

###### 

Adverse effects of different topical NSAIDs compared with placebo according to network meta-analysis in RCTs

  Treatment              OR (95% CI)              SUCRA (%)
  ---------------------- ------------------------ -----------
  Skin AE                                         
   Placebo               Reference                62.0
   Diclofenac gel         1.58 (0.58 to 4.87)     39.8
   Diclofenac solution    1.78 (0.79 to 4.08)     34.1
   Diclofenac patch       0.94 (0.11 to 7.11)     57.6
   Ketoprofen             1.17 (0.48 to 2.96)     52.8
   Eltenac                1.19 (0.20 to 6.57)     51.0
   Ibuprofen              0.93 (0.02 to 62.38)    54.4
   Nimesulide             1.14 (0.05 to 58.10)    50.5
   Salicylate             5.34 (0.68 to 43.38)    12.8
   Piroxicam              1.49 (0.34 to 7.11)     43.2
   Indomethacin           0.07 (0.00 to 2.37)     92.0
  GI AE                                           
   Placebo               Reference                45.3
   Diclofenac gel         1.25 (0.52 to 2.59)     30.1
   Diclofenac solution    0.99 (0.54 to 1.86)     46.3
   Diclofenac patch       0.99 (0.06 to 23.14)    47.9
   Ketoprofen             0.82 (0.41 to 1.64)     62.2
   Eltenac                0.62 (0.14 to 2.86)     69.6
   Salicylate             0.97 (0.21 to 4.54)     48.5
  Withdrawal due to AE                            
   Placebo               Reference                78.0
   Diclofenac gel         1.93 (0.94 to 3.91)     38.8
   Diclofenac solution    1.43 (0.73 to 2.86)     54.2
   Diclofenac patch       0.47 (0.03 to 3.70)     85.9
   Ketoprofen gel         1.40 (0.80 to 2.55)     54.8
   Eltenac gel            1.27 (0.11 to 35.04)    57.3
   Salicylate gel         16.83 (2.12 to 499.3)   37.5
   Indomethacin           3.22 (0.63 to 17.43)    27.2

AE, adverse effect; GI, gastrointestinal; RCTs, randomised controlled trials; SUCRA, surface under the cumulative ranking.

Adverse effects in observational studies {#s3e}
----------------------------------------

A total of seven observational studies[@R52] reported AEs of topical NSAIDs. Conventional meta-analysis showed that topical NSAID users did not exhibit a significantly higher rate of AEs than non-users (OR=1.19, 95% CI 0.92 to 1.55) (online [supplementary appendix 5](#SP1){ref-type="supplementary-material"}). Three (online [supplementary file 1)](#SP1){ref-type="supplementary-material"} case-control studies (including a nested case-control study)[@R52] examined serious systemic AEs such as GI bleeding, perforation, symptomatic peptic ulcers and acute renal failure associated with the use of topical NSAIDs. The risks of GI bleeding (OR=1.45, 95% CI 0.84 to 2.50), acute renal failure (OR=1.33, 95% CI 0.79 to 2.24) and symptomatic peptic ulcers (OR=1.00, 95% CI 0.60 to 1.70) were not significant. In addition, two case-control studies[@R55] examined the photosensitivity associated with topical NSAIDs. One[@R55] showed that the reporting OR for topical ketoprofen was 3.9 (95% CI 2.4 to 6.4) and the proportional reporting ratio was 3.4 (95% CI 2.1 to 5.5), versus other topical NSAIDs. The other[@R56] reported that the overall population attributable risk (PAR) for severe photosensitivity reactions linked to topical ketoprofen was 11.92% (--0.12 to 52.99) and the PAR for other topical NSAIDs was 2.47% (--3.17 to 29.99). Another case-control study[@R57] showed that topical NSAIDs might decrease the risk of squamous cell carcinoma (ever use vs non-use, incidence rate ratio (IRR): 0.85, 0.76 to 0.94) and malignant melanoma (IRR: 0.87, 0.80 to 0.95). Finally, no AEs associated with topical NSAIDs were reported in the cross-sectional study.[@R58]

Discussion {#s4}
==========

This is the first network meta-analysis to take into account all available evidence from RCTs directly or indirectly comparing topical NSAIDs in OA, thereby increasing the power of the study. For example, although there were only two trials for diclofenac patch (diclofenac patch vs placebo), there were 13 indirect comparisons (32 trials) through the network. The present study is also the first to summarise both RCTs and observational studies regarding the safety of topical NSAIDs. The main findings are: (1) topical NSAIDs are effective for the treatment of OA; (2) apart from topical salicylate acid, topical NSAIDs are not associated with serious GI and renal adverse events; (3) diclofenac patch is the most effective topical NSAIDs for pain relief, whereas topical piroxicam is the most effective topical NSAIDs for functional improvement.

Our previous conventional meta-analysis (13 RCTs) suggested that the efficacy of topical NSAIDs in OA only remained significant in the first 2 weeks compared with placebo.[@R28] According to the NICE OA Guidelines 2014, both effect estimate and the related 95% CI need to be greater than 0.5 SD, corresponding to a 1.2 cm decrease on a 10 cm visual analogue scale, which was considered to be the minimal clinically important difference (MCID).[@R5] Although the present conventional meta-analysis (36 RCTs) further confirms the time-dependent effects of topical NSAIDs, they did not reach the MCID at any time-point (online [supplementary](#SP1){ref-type="supplementary-material"} [appendix 5](#SP1){ref-type="supplementary-material"}). A similar pattern was also observed for functional improvement (online [supplementary](#SP1){ref-type="supplementary-material"} [appendix 5](#SP1){ref-type="supplementary-material"}). However, care must be taken in the interpretation of this result, as the studies pooled at each time point were different. This may partially explain why there were some fluctuations/variations. Further studies to examine the wear-off effect of topical NSAIDs for analgesia and functional improvement in OA are still warranted.

Previous systematic reviews have indicated that the overall effect size of topical NSAIDs in the treatment of knee or hip OA is 0.44 (95% CI 0.27 to 0.62) for pain relief.[@R28] However, the present study showed a smaller effect size (0.30, 95% CI 0.20 to 0.40), which may be explained by the recent publication of more high quality RCTs. The most novel finding is that diclofenac patch exhibited the largest effect on pain, even above that of diclofenac gel and solution. This may be due to the constant and continuous delivery of the active ingredient to the affected area by means of an occlusive bandage and slow release of the drug when compared with traditional topical formulations such as gel and solution.[@R63] It may also be due to the higher contextual effects of patches than creams/gels.[@R29] Due to the limited number of trials for other topical NSAIDs, we were unable to examine the different formulations for each topical NSAID. Thus more work needs to be done to confirm whether the patch formulation is indeed better than other formulations and what makes it better. Another possible explanation may be the shorter follow-up duration of diclofenac patch studies, as evidence suggests that the effects of topical NSAIDs may be gradually weakened with the passage of time.[@R28] However, a subgroup analysis conducted by restricting to trials with efficacy data at 1 or 2 weeks for all topical NSAIDs showed that diclofenac patch still exhibited the largest effect.

For the overall safety of topical NSAIDs, only RCT evidence has been systematically reviewed previously.[@R28] Although some individual RCTs have indicated higher skin reactions in topical NSAIDs than in placebo, this study did not confirm this. This may be due to the larger sample size lowering the likelihood of 'small study effects'. Another possible explanation is that a higher incidence of skin AEs may be attributed to specific topical NSAIDs (eg, diclofenac solution, diclofenac gel and salicylate gel).[@R60] Furthermore, there were two trials with significantly higher skin reactions in placebo groups than in active groups,[@R70] which may offset the effect of topical NSAIDs. It should be noted that one of the studies used hyaluronan gel as the placebo group.[@R70] The present study also found that topical NSAIDs overall exhibited a higher withdrawal rate due to AEs than the placebo group (OR=1.56). After excluding the trials with salicylate gel, which were associated with higher withdrawals due to AEs, we still observed a significant, but smaller AE risk (OR=1.47, 95% CI 1.15 to 1.90).

A recent network meta-analysis that compared seven different oral NSAIDs for the treatment of OA found that diclofenac 150 mg/day was the most effective for pain and function.[@R72] Several RCTs have confirmed that the clinical efficacy of topical diclofenac or ibuprofen is comparable with their corresponding oral forms, but with better tolerability and safety, which support the use of topical NSAIDs ahead of their oral counterparts.[@R68] In addition, the superior safety of topical NSAIDs in terms of GI, CV and renal risks has also been shown in the general population when compared with oral NSAIDs.[@R52] On the basis of our findings, topical NSAIDs can be readily prescribed for the treatment of OA irrespective of common comorbidities or other medications. The choice of topical NSAID may be made according to the order presented in [figure 3](#F3){ref-type="fig"}. The order should be based on both the SMD and its 95% CI and diclofenac patch is, therefore, the first line topical NSAID.

There are several caveats to this study. First, the number of RCTs for some topical NSAIDs is relatively small, especially in hand OA. Second, although the present study indicated that overall topical NSAIDs were effective and safe for OA, diclofenac patch was the most effective and only topical NSAID to reach the MCID in pain relief. Third, most of the follow-up periods of the included studies were relatively short, only examined the short (1--6 weeks) and medium-term (6--12 weeks) efficacy and safety of topical NSAIDs in RCTs. This is problematic for safety profiles as it is not possible to measure long-term outcomes for drug safety, such as GI and CV events. We, therefore, included the observational studies to overcome this limitation. Fourth, we only identified seven observational studies (218 074 participants) for the assessment of the safety of topical NSAIDs in the real world setting, irrespective of the target condition. A population-based and well-controlled cohort study is still needed to confidently determine a causal relationship between topical NSAIDs and AEs, especially CV AEs in people with OA. Fifth, like other meta-analyses, heterogeneity may affect the results of this meta-analysis. Last but not least, after excluding industry-funded/sponsored trials, only diclofenac patch was statistically superior to placebo for pain relief and none of the topical NSAIDs was better than placebo for functional improvement. This suggests that the efficacy of topical NSAIDs may be inflated by industry involvement. However, the limited number of remaining non-industry-funded/sponsored trials (only 12 trials for pain relief and 11 trials for functional improvement) may be too small to detect the difference, as these trials were small (ranging from 31 to 179 participants, median size 100). Further non-industry-funded/sponsored trials for topical NSAIDs are still needed, as this is a group of drugs with greater contextual effect than their oral counterparts[@R29] and it is more difficult to blind participants in trials and hence very easy to inflate their treatment benefits over placebo. We also attempted to examine whether trials with ≥100 participants per arm would give a different conclusion but failed as only 13 trials which fulfilled this criterion.

Conclusion {#s5}
==========

This systematic review identified 43 studies, comparing 36 RCTs (7900 patients with OA at any joint) and 7 observational studies (218 074 participants). Topical NSAIDs reduced pain and improved function in patients with OA. Diclofenac patches were the most effective topical NSAID for pain relief. No serious AEs were observed in randomised trials or observational studies in the general population. However, confirmation of the CV safety of topical NSAIDs still warrants further observational study.

###### What is already known on this topic?

-   Topical non-steroidal anti-inflammatory drugs (NSAIDs) are recommended for the treatment of osteoarthritis by many guidelines.

-   There are a number of topical NSAIDs. However, their relative efficacy remains largely unknown because there are few head-to-head comparative trials.

-   The safety of topical NSAIDs remains unclear, especially its systemic side effects such as gastrointestinal and cardiovascular events.

###### What are the new findings?

-   Topical non-steroidal anti-inflammatory drugs (NSAIDs) are effective to reduce pain and improve function in osteoarthritis.

-   Among all available topical NSAIDs, diclofenac patches were most effective for pain relief and piroxicam was the best option to improve function.

-   Other than salicylate gel, topical NSAIDs are safe. They are not associated with increased local or systemic adverse effects such as gastrointestinal and renal events; this can be concluded from both randomised trials and observational studies.
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